Pharnext SA (ALPHA.PA)
- Previous Close
0.1645 - Open
0.1700 - Bid --
- Ask --
- Day's Range
0.1432 - 0.1786 - 52 Week Range
0.1201 - 80,400,000.0000 - Volume
81,812 - Avg. Volume
28,002 - Market Cap (intraday)
90,878 - Beta (5Y Monthly) -316.97
- PE Ratio (TTM)
-- - EPS (TTM)
-99,954,999,296.0000 - Earnings Date Apr 26, 2024 - Apr 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs. Its products include PXT3003, a novel fixed-dose synergistic combination of baclofen, naltrexone, and sorbitol formulated that is in Phase III clinical trials for the treatment of Charcot-Marie-tooth disease type 1A; and PXT864 to treat amyotrophic lateral sclerosis. The company was incorporated in 2007 and is headquartered in Paris, France.
pharnext.comRelated News
Performance Overview: ALPHA.PA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALPHA.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALPHA.PA
Valuation Measures
Market Cap
99.73k
Enterprise Value
25.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
--
Enterprise Value/Revenue
166.82
Enterprise Value/EBITDA
-0.84
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-203.63%
Return on Equity (ttm)
--
Revenue (ttm)
1.82M
Net Income Avi to Common (ttm)
-31.55M
Diluted EPS (ttm)
-99,954,999,296.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
40.58k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-14.73M
Research Analysis: ALPHA.PA
Company Insights: ALPHA.PA
ALPHA.PA does not have Company Insights